SIREN : 447805011
DELPHARM TOURS is a French company founded 23 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in CHAMBRAY-LES-TOURS (37170), this company of category ETI shows in 2025 a revenue of 37.5 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 37 480 257 € | 36 005 792 € | 32 840 032 € | 28 152 226 € | 29 828 157 € | 33 621 530 € | 29 002 158 € | 33 563 477 € | 32 712 165 € |
| Net income | -3 229 378 € | 8 030 220 € | -2 885 776 € | -4 702 580 € | -3 411 759 € | -3 978 029 € | -1 683 756 € | 1 083 323 € | 1 482 452 € |
| EBITDA | 1 173 219 € | 14 971 884 € | 36 637 € | -2 394 860 € | -1 134 808 € | -1 548 818 € | 231 812 € | 3 334 870 € | 3 754 701 € |
| Net margin | -8.6% | 22.3% | -8.8% | -16.7% | -11.4% | -11.8% | -5.8% | 3.2% | 4.5% |
In 2025, DELPHARM TOURS achieves revenue of 37.5 M€. Revenue is growing positively over 9 years (CAGR: +1.5%). Vs 2024: +4%. After deducting consumption (10.9 M€), gross margin stands at 26.5 M€, i.e. a rate of 71%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.2 M€, representing 3.1% of revenue. Warning negative scissor effect: despite revenue change (+4%), EBITDA varies by -92%, reducing margin by 38.5 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Net income is negative at -3.2 M€ (-8.6% of revenue), which will impact equity.
37 480 257 €
26 534 404 €
1 173 219 €
-2 425 258 €
-3 229 378 €
3.1%
The debt ratio (= Financial debt / Equity x 100) stands at 109%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 36%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 61.6 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 0.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
108.61%
35.674%
0.892%
61.58
52.5%
In 2025, the debt ratio of DELPHARM TOURS (108.61) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2025, the financial autonomy of DELPHARM TOURS (35.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2025, the repayment capacity of DELPHARM TOURS (61.58) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 107.85. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 66.8x. Operating income very largely covers interest expenses: high safety margin.
107.847
66.81
In 2025, the liquidity ratio of DELPHARM TOURS (107.85) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2025, the interest coverage of DELPHARM TOURS (66.8x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 11 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 88 days. Excellent situation: suppliers finance 77 days of the operating cycle (retail model). Inventory turnover is 70 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 43 days of revenue, i.e. 4.5 M€ to permanently finance. Notable WCR improvement over the period (-46%), freeing up cash.
4 489 760 €
11 j
88 j
70 j
43 j
Compare DELPHARM TOURS with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of DELPHARM TOURS in 2025 is 37.5 M€.
DELPHARM TOURS recorded a net loss in 2025.
The headquarters of DELPHARM TOURS is located in CHAMBRAY-LES-TOURS (37170), in the department Indre-et-Loire.
The tax return of DELPHARM TOURS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
DELPHARM TOURS operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.